Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Kelun-Biotech’s Lead ADC Meets Endpoint in Phase III Triple Negative Breast Cancer Trial

publication date: Aug 14, 2023

Sichuan Kelun-Biotech reported that its TROP2 ADC met the primary progression-free survival endpoint at an interim analysis in a China Phase III trial in patients with triple-negative breast cancer. Based on the results, Kelun-Biotech will discuss submitting an NDA of SKB264 with China’s Center for Drug Evaluation. The company did not release the results. In 2022, Kelun-Biotech out-licensed global rights (ex-China) for SKB264 to MSD (Merck) in one of three ADC partnerships between the two companies that had a combined value of $12 billion. Kelun-Biotech expects SKB264 will be the first TROP2 ADC approved in China. More details....

Stock Symbol: (HK: 6990)

Share this with colleagues: